Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LODE | EFFECT | neutral | 4/10 | Comstock Inc.'s shelf registration statement (S-3) became effective on May 6, 2026, covering up to $200 million in secur | May 7, 2026 |
| VOR | EFFECT | neutral | 3/10 | Vor Biopharma's S-3 registration statement (File No. 333-295346) became effective on May 6, 2026, enabling the resale of | May 7, 2026 |
| NCEL | EFFECT | neutral | 3/10 | NewcelX Ltd.'s shelf registration statement (File No. 333-290516) became effective on May 6, 2026, allowing the company | May 7, 2026 |
| ZLAB | 8-K | bearish | 6/10 | Zai Lab reported Q1 2026 total revenue of $99.6M, down 6% YoY from $106.5M, and product revenue of $95.6M, down 10% YoY. | May 7, 2026 |
| GENB | 8-K | bearish | 6/10 | Generate Biomedicines reported Q1 2026 collaboration revenue of $7.2M (down 18% YoY from $8.8M) and a net loss of $61.7M | May 7, 2026 |
| OCS | PRESS-RELEASE | bullish | 7/10 | Oculis announced FDA Special Protocol Assessment (SPA) agreement for the PIONEER-1 Phase 3 trial of Privosegtor in optic | May 7, 2026 |
| CYTK | PRESS-RELEASE | bearish | 6/10 | Cytokinetics priced a $700 million public offering of 9.86 million shares at $71.00 per share, with an underwriter optio | May 6, 2026 |
| SPTX | 3 | neutral | 3/10 | General Atlantic entities filed Form 3 initial beneficial ownership disclosures for Seaport Therapeutics (SPTX), reporti | May 6, 2026 |
| RDPTF | 3 | neutral | 2/10 | Form 3 initial beneficial ownership filing for Dr. Dimitris Voliotis, newly appointed Chief Medical Officer of Radiophar | May 6, 2026 |
| MPLT | CLUSTER | bearish | 5/10 | MapLight Therapeutics insiders sold a combined $1.3M in open-market sales over a 7-day window, including the CEO, CFO, C | May 6, 2026 |
| TVTX | CLUSTER | bearish | 6/10 | Multiple Travere Therapeutics insiders, including the CEO, CFO, and CMO, sold shares in the days following strong Q1 202 | May 6, 2026 |
| TOMZ | PRESS-RELEASE | neutral | 1/10 | TOMI Environmental Solutions, Inc. announced it will host a conference call on May 8, 2026 to discuss its Q1 2026 result | May 6, 2026 |
| LABT | 3 | neutral | 2/10 | Joseph Edward Tucker filed a Form 3 initial statement of beneficial ownership, reporting zero shares of Lakewood-Amedex | May 6, 2026 |
| ARQT | CLUSTER | neutral | 2/10 | Two insiders sold a total of $239K in ARQT shares, representing only 0.008% of market cap. This is trivial and routine a | May 6, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer were published in NE | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Two officers sold a total of $1.13M in stock post-strong Q1 earnings; nine directors received non-cash stock grants. Sal | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Insider cluster at West Pharmaceutical Services shows $1.13M in open-market sales by two non-C-suite executives shortly | May 6, 2026 |
| IONS | CLUSTER | neutral | 3/10 | Two IONS directors sold approximately $5.1M in stock, which is trivial relative to the company's $12.4B market cap (0.04 | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Two insiders at West Pharmaceutical Services sold a total of $1.13M in shares, representing a trivial 0.005% of market c | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Insider cluster at West Pharmaceutical Services includes two small open-market sales ($1.13M total) and three non-cash d | May 6, 2026 |
| WST | CLUSTER | neutral | 2/10 | Two insiders sold $1.13M worth of WST shares (0.005% of market cap) following strong Q1 earnings. The sales are immateri | May 6, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO and CFO exercised stock options and sold a small number of shares (total ~$558K) coincident with Q1 2026 earnings re | May 6, 2026 |
| CMMB | 6-K | neutral | 2/10 | Chemomab Therapeutics filed a 6-K reporting results of its annual general meeting held on May 5, 2026. Shareholders appr | May 6, 2026 |
| ZOMDF | 8-K | bullish | 6/10 | Zomedica reported record Q1 2026 revenue of $8.8M (+35% YoY), driven by diagnostics growth (+73%) and consumables (+22%) | May 6, 2026 |
| ACAD | 8-K | bearish | 6/10 | Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M ( | May 6, 2026 |
| DYN | 144 | neutral | 2/10 | Atlas Venture Fund XI, L.P. filed a Form 144 indicating intent to sell 43,621 shares of Dyne Therapeutics (DYN) valued a | May 6, 2026 |
| DYN | 144 | neutral | 2/10 | Atlas Venture Associates XI, L.P., a major venture capital shareholder, filed a Form 144 indicating intent to sell 428 s | May 6, 2026 |
| PAHC | 8-K | bullish | 6/10 | Phibro Animal Health reported Q3 FY2026 results with net sales of $383.5M (+10% YoY) and adjusted diluted EPS of $0.76, | May 6, 2026 |
| DMAC | 8-K | bearish | 6/10 | DiaMedica reported Q1 2026 EPS of -$0.19, missing consensus of -$0.17 by 11.8%. Net loss widened to $10.0M from $7.7M a | May 6, 2026 |
| ALVO | PRESS-RELEASE | bearish | 7/10 | Alvotech reported Q1 2026 revenue of $105.9M (down 20% YoY) and a GAAP EPS of -$0.37, far below the $0.06 consensus, due | May 6, 2026 |